Surprising Early Warning Signs and the Latest in Diagnostics for Parkinson's Disease

Overview

In this report, we will cover early warning signs that can appear decades before the onset of classical Parkinson's symptoms, and the latest in diagnostic tests that can identify Parkinson's disease earlier. This presents a window with a real opportunity to alter disease progression. This report is the second in a five-part series on Parkinson's Disease. Report 1 covered environmental risk factors; reports 3-5 will address exercise, nutrition, and the gut-brain connection.

Understanding the Disease

Before diving in, let's take a moment to understand what's happening in Parkinson's disease at a biological level. Alpha-synuclein is a small protein found at nerve terminals throughout the brain and body, where it helps regulate the release of neurotransmitters like dopamine. In Parkinson's disease, this protein misfolds and clumps together. Critically, misfolded alpha-synuclein spreads from cell to cell, "seeding" misfolding in neighboring neurons over many years, and progressively degrading the process of neurotransmitter release.

The Braak staging hypothesis proposes that this pathology follows a predictable pattern, starting in the lower brainstem and olfactory system before spreading upward to the substantia nigra (causing motor symptoms) and eventually the cortex (causing cognitive decline). While 51-83% of patients follow this pattern—and some cases show different distributions—the model explains why non-motor symptoms like sleep disturbances and loss of smell often appear years before tremor and slowness.

Early Warning Signs of Parkinson's Disease

When Dreams Break Through

During normal dreaming or REM sleep, the brain paralyzes the body's muscles—a protective mechanism controlled by specific brainstem nuclei. In REM sleep behavior disorder (RBD), this paralysis fails, causing people to physically act out their dreams: punching, kicking, shouting, or falling out of bed. RBD affects roughly 1% of the U.S. population and 2% of adults over 50, though many cases go unrecognized since nearly half of affected individuals are unaware of their nighttime behaviors.

The connection to neurodegeneration is striking. The largest study of RBD patients (1,280 patients from 24 centers) found that 6.3% convert to a neurodegenerative disease each year, with 73.5% converting within 12 years. More than 80% of people with isolated RBD eventually develop Parkinson's, dementia with Lewy bodies, or multiple system atrophy. RBD is not merely a risk factor—the same brainstem nuclei that control sleep paralysis are among the first structures affected by alpha-synuclein pathology.

Smell, Constipation and Mood

Loss of smell often appears 4-6 years before motor symptoms in Parkinson's Disease. Constipation may appear up to 20 years before diagnosis, reflecting early alpha-synuclein buildup in the gut's nervous system—supporting a theory that Parkinson's may begin in the gut and spread to the brain via the vagus nerve (we'll explore this gut-brain connection in Report 5). Depression and anxiety frequently precede motor symptoms by several years. While constipation and mood changes are common in the general population, their co-occurrence with smell loss should prompt neurological evaluation.

Breakthrough Diagnostic Tests

The past few years have brought major advances in Parkinson's diagnostics. We now have tests that detect disease pathology years before symptoms emerge.

Skin Biopsy (Syn-One Test)

Because alpha-synuclein pathology affects nerves throughout the body—not just the brain—misfolded protein accumulates in small nerve fibers in the skin. A 2024 NIH-funded study in JAMA validated this approach across 30 sites and 428 patients, detecting alpha-synuclein in 93% of participants with Parkinson's. The procedure involves small skin biopsies.

The Syn-One Test is commercially available and a listing of providers who perform the test is available. However, because it requires punch biopsies that many neurologists don't routinely perform, some practices may need to coordinate with dermatology or train staff on the procedure—a workflow consideration that could slow adoption despite the test's clinical value.

DaTscan

This FDA-approved imaging technique uses a radioactive tracer to visualize dopamine transporters in the brain. It reliably distinguishes Parkinson's from essential tremor (a common misdiagnosis) and confirms dopamine loss in patients with early warning symptoms. However, DaTscan cannot differentiate Parkinson's from other parkinsonian syndromes and may be normal in the early pre-motor phase—limitations that newer tests like SAA and skin biopsy address.

Alpha-Synuclein Seed Amplification Assays (SAA)

These tests exploit how misfolded alpha-synuclein "seeds" misfolding in normal protein—like a chain reaction. By adding a sample to normal protein in a test tube, even tiny amounts of pathological protein are amplified into detectable aggregates. SAA testing is now clinically available in the United States. Amprion's SAAmplify test—the only commercially available SAA—can be ordered through Mayo Clinic Laboratories as of March 2025. The test requires a spinal tap to obtain cerebrospinal fluid, which means it's typically reserved for patients where diagnostic certainty is important—such as those with RBD or unexplained symptoms. Blood-based SAA tests are rapidly approaching clinical implementation.

On the Horizon

AI-Based Blood Biomarker Panels

A 2024 study in Nature Communications found that machine learning analysis of eight blood proteins could diagnose established Parkinson's with 100% accuracy. More remarkably, when tested in 72 patients with REM behavior disorder, the panel predicted who would develop Parkinson's up to seven years before symptom onset.

AI-Enhanced MRI (AIDP)

AI can detect subtle brain changes invisible to the human eye that distinguish Parkinson's from look-alike conditions. A 2025 multicenter study in JAMA Neurology validated this approach across 21 sites, achieving 96% accuracy distinguishing Parkinson's from Atypical Parkinsonian Syndromes, with predictions confirmed by autopsy in 94% of cases. Since current diagnostic accuracy hovers between 55-78% in the first five years, AIDP—which works on standard MRI scanners—could significantly improve early care.

Epigenetic and RNA-Based Tests

Researchers are exploring whether chemical modifications to DNA (methylation patterns) and small RNA molecules (microRNAs) in blood could serve as Parkinson's biomarkers. A 2024 study in Annals of Neurology identified consistent methylation differences in a gene (CYP2E1) involved in pesticide metabolism���potentially linking environmental exposure to disease. MicroRNA panels have shown 82% sensitivity and 80% specificity in distinguishing patients from controls. These approaches remain in research phase but could eventually enable simple blood tests that capture both genetic and environmental risk factors.

Why Early Diagnosis Matters

For decades, the rationale for early Parkinson's diagnosis was limited—we could treat symptoms but couldn't change disease course. That calculus is shifting. In April 2024, the New England Journal of Medicine published results from a Phase 2 trial showing that lixisenatide, a diabetes drug, slowed motor symptom progression in early-stage Parkinson's patients over 12 months—the placebo group worsened while the treated group held steady. A four-year follow-up of prasinezumab (an antibody targeting alpha-synuclein) showed sustained slowing of motor progression compared to natural history, and Roche announced in June 2025 that it will advance the drug to Phase 3 trials.

These are not cures—but they represent the first credible signals that we may be able to slow Parkinson's progression. The catch: by the time tremor appears, more than half of dopamine neurons are already gone. Disease-modifying therapies will likely work best when started early, before substantial brain damage has occurred. This is precisely why the diagnostic advances described in this report matter. Tests like skin biopsy and seed amplification assays can identify Parkinson's pathology in at-risk patients—like those with RBD or smell loss who haven't yet developed motor symptoms—creating a window for early intervention that didn't exist five years ago.